Azar points to Amgen, Merck and Gilead as evidence of progress in curbing drug prices
Amgen, as well as Merck and Gilead, are among examples the Trump administration pointed to of companies that have cut list prices on certain drugs. (Amgen)
Despite a slew of recent drug price hikes, the Trump administration claims it's seeing signs of progress in its efforts to curb the price of prescriptions.
Since May, when the president first announced his drug pricing blueprint, drug companies took 57% fewer price increases on brand-name drugs compared with the same period in 2017, Health and Human Services Secretary Alex Azar said on Tuesday.
“Some companies, such as Amgen, Merck, and Gilead, have cut the list price on certain drugs, and early data suggests that the 2019 price increases have been smaller and fewer in number than we saw in 2018," Azar told the Council for Affordable Health Coverage at an event in D.C. on Tuesday. “But drug companies have a lot further to go."
13th Partnering with ACOS & IDNS Summit
This two-day summit taking place on June 10–11, 2019, offers a unique opportunity to have invaluable face-to-face time with key executives from various ACOs and IDNs from the entire nation – totaling over 3.5 million patients served in 2018. Exclusively at this summit, attendees are provided with inside information and data from case studies on how to structure an ACO/IDN pitch, allowing them to gain the tools to position their organization as a “strategic partner” to ACOs and IDNs, rather than a merely a “vendor.”